A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.Zefei Jiang, Hua Yang, Yueyin Pan et al.|Journal of Clinical Oncology|2022Cited by 36
CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trialJia Liu, Lin Shen, Michelle Frances Morris et al.|Nature Medicine|2025Cited by 29